389 related articles for article (PubMed ID: 9652994)
1. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial.
Reginster JY; Meurmans L; Zegels B; Rovati LC; Minne HW; Giacovelli G; Taquet AN; Setnikar I; Collette J; Gosset C
Ann Intern Med; 1998 Jul; 129(1):1-8. PubMed ID: 9652994
[TBL] [Abstract][Full Text] [Related]
2. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
[TBL] [Abstract][Full Text] [Related]
3. Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate.
Ringe JD; Kipshoven C; Cöster A; Umbach R
Osteoporos Int; 1999; 9(2):171-8. PubMed ID: 10367046
[TBL] [Abstract][Full Text] [Related]
4. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy.
Meunier PJ; Sebert JL; Reginster JY; Briancon D; Appelboom T; Netter P; Loeb G; Rouillon A; Barry S; Evreux JC; Avouac B; Marchandise X
Osteoporos Int; 1998; 8(1):4-12. PubMed ID: 9692071
[TBL] [Abstract][Full Text] [Related]
5. Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study.
Alexandersen P; Riis BJ; Christiansen C
J Clin Endocrinol Metab; 1999 Sep; 84(9):3013-20. PubMed ID: 10487657
[TBL] [Abstract][Full Text] [Related]
6. Monofluorophosphate combined with hormone replacement therapy in postmenopausal osteoporosis. An open-label pilot efficacy and safety study.
Ringe JD; Setnikar I
Rheumatol Int; 2002 May; 22(1):27-32. PubMed ID: 12120908
[TBL] [Abstract][Full Text] [Related]
7. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
[TBL] [Abstract][Full Text] [Related]
8. In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study.
Guaydier-Souquières G; Kotzki PO; Sabatier JP; Basse-Cathalinat B; Loeb G
Osteoporos Int; 1996; 6(2):171-7. PubMed ID: 8704358
[TBL] [Abstract][Full Text] [Related]
9. Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate.
Ringe JD; Dorst A; Kipshoven C; Rovati LC; Setnikar I
Osteoporos Int; 1998; 8(1):47-52. PubMed ID: 9692077
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of sodium fluoride (60 mg) +/- estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not vertebral fractures.
Gutteridge DH; Stewart GO; Prince RL; Price RI; Retallack RW; Dhaliwal SS; Stuckey BG; Drury P; Jones CE; Faulkner DL; Kent GN; Bhagat CI; Nicholson GC; Jamrozik K
Osteoporos Int; 2002; 13(2):158-70. PubMed ID: 11908491
[TBL] [Abstract][Full Text] [Related]
11. Treatment of vertebral osteoporosis with disodium monofluorophosphate: comparison with sodium fluoride.
Delmas PD; Dupuis J; Duboeuf F; Chapuy MC; Meunier PJ
J Bone Miner Res; 1990 Mar; 5 Suppl 1():S143-7. PubMed ID: 2339624
[TBL] [Abstract][Full Text] [Related]
12. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
[TBL] [Abstract][Full Text] [Related]
13. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
McCloskey E; Selby P; Davies M; Robinson J; Francis RM; Adams J; Kayan K; Beneton M; Jalava T; Pylkkänen L; Kenraali J; Aropuu S; Kanis JA
J Bone Miner Res; 2004 May; 19(5):728-36. PubMed ID: 15068495
[TBL] [Abstract][Full Text] [Related]
14. Addition of monofluorophosphate to estrogen therapy in postmenopausal osteoporosis: a randomized controlled trial.
Reid IR; Cundy T; Grey AB; Horne A; Clearwater J; Ames R; Orr-Walker BJ; Wu F; Evans MC; Gamble GD; King A
J Clin Endocrinol Metab; 2007 Jul; 92(7):2446-52. PubMed ID: 17440020
[TBL] [Abstract][Full Text] [Related]
15. Slow-release sodium fluoride in the management of postmenopausal osteoporosis. A randomized controlled trial.
Pak CY; Sakhaee K; Piziak V; Peterson RD; Breslau NA; Boyd P; Poindexter JR; Herzog J; Heard-Sakhaee A; Haynes S; Adams-Huet B; Reisch JS
Ann Intern Med; 1994 Apr; 120(8):625-32. PubMed ID: 8135445
[TBL] [Abstract][Full Text] [Related]
16. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial.
Greenspan SL; Bone HG; Ettinger MP; Hanley DA; Lindsay R; Zanchetta JR; Blosch CM; Mathisen AL; Morris SA; Marriott TB;
Ann Intern Med; 2007 Mar; 146(5):326-39. PubMed ID: 17339618
[TBL] [Abstract][Full Text] [Related]
17. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
Wimalawansa SJ
Am J Med; 1998 Mar; 104(3):219-26. PubMed ID: 9552083
[TBL] [Abstract][Full Text] [Related]
18. Fluoride pharmacokinetics and changes in lumbar spine and hip bone mineral density.
Patel S; Chan JK; Hosking DJ
Bone; 1996 Dec; 19(6):651-5. PubMed ID: 8968033
[TBL] [Abstract][Full Text] [Related]
19. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.
Cummings SR; Black DM; Thompson DE; Applegate WB; Barrett-Connor E; Musliner TA; Palermo L; Prineas R; Rubin SM; Scott JC; Vogt T; Wallace R; Yates AJ; LaCroix AZ
JAMA; 1998 Dec 23-30; 280(24):2077-82. PubMed ID: 9875874
[TBL] [Abstract][Full Text] [Related]
20. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
